الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
The pathophysiology of diabetic nephropathy includes hemodynamic changes, oxidative stress, the formation of advanced glycation end products, fibrosis and epigenetic regulatory processes, so they are potential targets for future drug therapy, as there is no specific treatment for DN.
Mesenchymal stem cells are multipotent progenitor cells which are non-hematopoietic and can differentiate into many types of cells. Stem cell therapy is considered as a new promising approach for treatment of diabetes and its complications.
MSCs play a part in DN treatment mainly in two pathways, including hyperglycemia control and kidney impairment alleviation. MSCs can alleviate high blood glucose by promoting regeneration of islet cells and reducing insulin resistance, as well as improving islet function, thereby lessening the kidney injury resulting from high blood glucose. MSCs can also directly rescue kidney damage through regulation of the immune environment, reducing fibrosis formation, and promoting angiogenesis
The aim of our work was to study the potential therapeutic effects of human mesenchymal stem cells on experimentally induced diabetic nephropathy.
This study was done on three experimental groups, each group was seven albino rat of local strain. The groups included control group, Streptozotocin (STZ) induced diabetic kidney disease group (DKD) by multiple low dose injection of STZ (40 mg/kg BW intraperitoneally) for 5 consecutive days to induce a slowly progressive diabetes mellitus, and diabetic kidney disease treated with mesenchymal stem cells group (DKD+MSCs).